Abstract
Rapid development in digital technology has offered vast metrics to strengthen patient-reported outcome (PRO) databases. Globally, PRO endpoints have gained momentum in addition to traditional clinical trial endpoints, thereby integrating patients’ perspective into drug approvals. The aim of this research is to evaluate the role of PRO endpoints in decision making process of European Medicines Agency (EMA) for drug approval.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
